Comment on Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. [Lancet Oncol. 2018]
Adjuvant treatment for EGFR-mutated non-small cell lung cancer: Do we have a major breakthrough? / Roviello G.; Imperatori M.; Aieta M.; Sollitto F.; Landriscina M.. - In: JOURNAL OF THORACIC DISEASE. - ISSN 2072-1439. - ELETTRONICO. - 10:(2018), pp. S2114-S2118. [10.21037/jtd.2018.06.114]
Adjuvant treatment for EGFR-mutated non-small cell lung cancer: Do we have a major breakthrough?
Roviello G.;
2018
Abstract
Comment on Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. [Lancet Oncol. 2018]
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
jtd-10-S18-S2114.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
140.02 kB
Formato
Adobe PDF
|
140.02 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
